To reach the next value inflection
LicenseRx asset brief
New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer
Probability of Success
16% · grade B · Medium data confidence
Model PoS 16% (grade B, medium data confidence). Strongest signals: Indication pull, IP position. Biggest drag: Modality feasibility.
Data maturity (22%)
49
Early / Discovery; efficacy signal, human data, clinical reference.
IP position (16%)
72
Patent filed/pending -- prosecution ongoing.
Modality feasibility (14%)
66
Biologic/antibody -- solid path but higher CMC burden.
Indication pull (14%)
87
Oncology -- active buyer appetite. Public text flags unmet need.
Competitive whitespace (12%)
78
Under-served segment; crowded oncology field; multi-modal differentiation.
Translational evidence (12%)
78
Public evidence mentions: clinical, efficacy, human, patient.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →